Adaptive Biotechnologies (NASDAQ:ADPT) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.
Analyst Ratings
This is a breakdown of recent ratings for Adaptive Biotechnologies and Krystal Biotech, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Adaptive Biotechnologies | 0 | 2 | 4 | 0 | 2.67 |
| Krystal Biotech | 0 | 0 | 6 | 0 | 3.00 |
Adaptive Biotechnologies presently has a consensus price target of $61.40, suggesting a potential upside of 45.39%. Krystal Biotech has a consensus price target of $101.00, suggesting a potential upside of 38.85%. Given Adaptive Biotechnologies' higher probable upside, equities analysts plainly believe Adaptive Biotechnologies is more favorable than Krystal Biotech.
Profitability
This table compares Adaptive Biotechnologies and Krystal Biotech's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Adaptive Biotechnologies | -132.32% | -20.15% | -13.09% |
| Krystal Biotech | N/A | -10.72% | -10.40% |
Earnings and Valuation
This table compares Adaptive Biotechnologies and Krystal Biotech's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Adaptive Biotechnologies | $85.07 million | 69.11 | $-68,610,000.00 | ($1.01) | -41.81 |
| Krystal Biotech | N/A | N/A | $-19,090,000.00 | ($1.20) | -60.62 |
Krystal Biotech has lower revenue, but higher earnings than Adaptive Biotechnologies. Krystal Biotech is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Adaptive Biotechnologies has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.
Institutional and Insider Ownership
80.8% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 73.1% of Krystal Biotech shares are held by institutional investors. 22.2% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 27.4% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Krystal Biotech beats Adaptive Biotechnologies on 8 of the 13 factors compared between the two stocks.
